research Novel inhibitors of 5α-reductase
New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
Search
for
Sort by
Research
660-690 / 1000+ results research Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.
research FINASTERIDE INFLUENCE ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY
Finasteride increases P-glycoprotein activity in the liver and kidney.
research Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
research An overview on 5α-reductase inhibitors
5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
research Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone.
GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
research Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase
LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research Progesterone-induced spike-wave discharges are inhibited by finasteride
Finasteride blocks progesterone's effect on brain activity linked to epilepsy.
research Steroid 5α-reductase inhibition by polymethoxyflavones
Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
research Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Finasteride is most linked to drug-induced erectile dysfunction.
research Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main Protease
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
research Physiologic functions of PP2A: Lessons from genetically modified mice
Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.
research Drug–Drug Coamorphous System of Tadalafil and Finasteride for Enhanced Pharmaceutical Performance
Combining tadalafil and finasteride improves their solubility and effectiveness.
research Screen steroid 5 alpha-reductase inhibitors in vitro by high performance liquid chromatography
The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
research Pharmacological Activity and Clinical Use of PDRN
PDRN helps repair tissue and improve wound healing with a high safety profile.
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
research A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.
research Synthesis and Evaluation of 2‘-Substituted 4-(4‘-Carboxy- or 4‘-carboxymethylbenzylidene)-N-acylpiperidines: Highly Potent and in Vivo Active Steroid 5α-Reductase Type 2 Inhibitors
Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
research Steroid 5α-Reductase Inhibitors
New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
research Repurposing Finasteride as a quorum sensing inhibitor in Pseudomonas aeruginosa
Finasteride may help treat Pseudomonas aeruginosa infections by reducing its harmful activities.
research Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men
research In Vivo Time-Dependent Inhibition of Human Steroid 5a-Reductase by Finasteride
Finasteride poorly inhibits type 1 5AR, affecting its effectiveness.
research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research 5α-Reductase Inhibitors, Chemical and Clinical Models
Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.
research Pharmacodynamics and pharmacokinetics of P-3074, a new finasteride topical solution, administered at four different doses
P-3074 effectively blocks scalp DHT better than oral finasteride.
research Molecular mechanism for transcriptional regulation of the parathyroid hormone gene by Epiprofin
Epiprofin suppresses parathyroid hormone gene activity, helping regulate calcium levels and could be a treatment target for hyperparathyroidism.
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.